GEN Exclusives

More »

GEN News Highlights

More »
Feb 4, 2008

Seaside Proffers $4.5M to Support Discovery Activities in Fragile X Syndrome at Vanderbilt

  • Seaside Therapeutics granted a $4.5 million collaborative research contract with Vanderbilt University Medical Center to discover compounds to suppress the manifestations of fragile X syndrome.

    Past research has indicated that excessive signaling through metabotropic glutamate receptor subtype 5 (mGluR5) may be responsible for the neurological and psychiatric consequences of fragile X syndrome.

    Seaside believes that selective inhibition of this receptor could reduce or eliminate the devastating effects of this disease. Scientists at Vanderbilt have identified more than 400 novel compounds belonging to multiple chemical classes that inhibit mGluR5.

    Vanderbilt researchers will use medicinal chemistry, molecular biology, pharmacology, and efficacy studies to discover and develop drug candidates. Seaside will contribute scientific and drug development expertise. The company will also select compounds from the collaboration to carry forward into clinical development.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?